1-3 of 3
Paul Foster
Close
Sort by
Journal Articles

ARC-12: Phase 1/1b Study to Evaluate Safety and Tolerability of AB308 + Zimberelimab (AB122) in Advanced Malignancies

Sikander Ailawadhi, Paul Foster, Sarah Ryba, Michael Scharville, Assem El-Baghdady
Journal: Blood
Blood (2021) 138 (Supplement 1): 1409.
https://doi.org/10.1182/blood-2021-153007
Published: 2021
Journal Articles

A Critical Role for Donor-Derived IL-22 in Cutaneous Chronic Gvhd

Kate H Gartlan, PhD, Hemamalini Bommiasamy, PhD, Katelyn Paz, Andrew Wilkinson, Mary Owen, Dawn Reichenbach, PhD, Tatjana Banovic, PhD MD, Kimberly Wehner, Faith Buchanan, Antiopi Varelias, PhD, Rachel Kuns, Karshing Chang, Yuri Fedoriw, MD, Thomas C. Shea, MD, James M. Coghill, Jr., MD, Michael Zaiken, Maximilian Plank, PhD, Paul Foster, Andrew Clouston, Bruce Blazar, MD, Jonathan S Serody, MD, Geoffrey R Hill, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 69.
https://doi.org/10.1182/blood.V130.Suppl_1.69.69
Published: 2017
Journal Articles

Evaluation of Baseline Body-Weight Dosing of Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL).

Gregory Wiseman, MD, Peter Conti, MD, Katie Vo, Russell J. Schilder, MD, Paul Foster, MD, Leo I. Gordon, MD, Christos Emmanouilides, MD, Dan Silverman, MD, Thomas E. Witzig, MD, Arturo Molina, MD
Journal: Blood
Blood (2004) 104 (11): 2634.
https://doi.org/10.1182/blood.V104.11.2634.2634
Published: 2004